Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialSun Young Rha, Xiaochun Zhang, Fernando Rivera et al.|The Lancet Oncology|2023Cited by 614
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 StudyAkihito Kawazoe, Reinhard Depenbusch, Rui‐Hua Xu et al.|Journal of Clinical Oncology|2024Cited by 77
Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experienceNalinie Joharatnam‐Hogan, Khurum Khan, Daniel Hochhauser et al.|Therapeutic Advances in Medical Oncology|2020Cited by 37